Mesenchymal stem-cell immunosuppressive capabilities: therapeutic implications in islet transplantation. by Ding, Y, Bushell, A, Wood, K

How regenerative medicine may contribute to the achievement of an immunosuppression-free state. by Orlando, G, Wood, K, Soker, S, Stratta, R

Th17 cells in alemtuzumab-treated patients: the effect of long-term maintenance immunosuppressive therapy. by Hester, J, Mills, N, Shankar, S, Carvalho-Gaspar, M, Friend, P, Wood, K

“…BACKGROUND: Leukocyte depletion at the time of transplantation with alemtuzumab (Campath-1H) has been demonstrated to be a potential strategy for reducing long-term exposure to immunosuppressive drugs. Although the impact of alemtuzumab treatment on the immune system has been explored, the effects of long-term immunosuppressive therapy in alemtuzumab-treated patients still need to be elucidated. …”

Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. by Trzonkowski, P, Zilvetti, M, Chapman, S, Wieckiewicz, J, Sutherland, A, Friend, P, Wood, K

“…Alemtuzumab (CAMPATH-1H) is a depleting agent introduced recently in transplantation and often used with reduced maintenance immunosuppression. In the current study we investigated the immune response of 13 kidney allograft recipients treated with alemtuzumab followed by weaned immunosuppression with reduced dose of mycophenolate mofetil (MMF) and tacrolimus. …”

Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. by Ding, Y, Xu, D, Feng, G, Bushell, A, Muschel, R, Wood, K

“…</p> <p><strong>RESEARCH DESIGN AND METHODS</strong> We investigated the molecular mechanisms underlying the immunosuppressive effects of MSCs in vitro and in vivo.…”

Application of operational tolerance signatures are limited by variability and type of immunosuppression in renal transplant recipients: A cross-sectional study. by Bottomley, M, Chen, M, Fuggle, S, Harden, P, Wood, K

“… <h4>Background</h4> <p>Renal transplant recipients (RTR) frequently develop complications relating to chronic immunosuppression. Identifying RTR who could safely reduce immunosuppression is therefore highly desirable. …”

Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. by Trzonkowski, P, Zilvetti, M, Friend, P, Wood, K

“…The impact of immunosuppressive drugs on leukocytes that escape depletion was also evaluated in vitro. …”

Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. by Trzonkowski, P, Zilvetti, M, Friend, P, Wood, K

“…The impact of immunosuppressive drugs on leukocytes that escape depletion was also evaluated in vitro. …”

Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients by Brook, MO, Hester, J, Petchey, W, Rombach, I, Dutton, S, Bottomley, MJ, Black, J, Abdul-Wahab, S, Bushell, A, Lombardi, G, Wood, K, Friend, P, Harden, P, Issa, F

“…Control participants will receive a standard basiliximab-based immunosuppression regimen with long-term tacrolimus and mycophenolate mofetil immunosuppression. …”

The utilisation of biomarkers of a reduced immune response to predict squamous cell carcinoma in long-term renal transplant recipients by Bottomley, M

Subjects:

Modelling and characterisation of in vivo human skin graft rejection for the investigation of regulatory T cell therapy in vascularised composite allotransplantation by Issa, F

“…It stimulates a vigorous immune response and is highly susceptible to rejection, even in the presence of potent immunosuppression. In order to expand the field of VCA transplantation and improve outcomes, the morbidity and mortality associated with immunosuppression need to be minimised or eliminated. …”

The germinal centre reaction and follicular T cells in alloantibody formation by Wallin, E

“…Understanding more about how these antibodies are produced, and how immunosuppression affects cells producing them, may allow both prediction of those at risk, and a mechanism for preventing or minimising antibody production, therefore improving graft lifespan. …”

Identification, selection, and expansion of non-gene modified alloantigen-reactive Tregs for clinical therapeutic use by Alzhrani, A, Bottomley, M, Wood, K, Hester, J, Issa, F

“…Transplantation is limited by the need for life-long pharmacological immunosuppression, which carries significant morbidity and mortality. …”

Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials by Sawitzki, B, Harden, PN, Reinke, P, Roberts, ISD, Hester, J, van der Net, JB, Petchey, W, Issa, F, Morris, PJ, Bushell, A, Friend, P, Wood, K, Geissler, EK, Et al.

“…<p><strong>Background:</strong>&nbsp;Use of cell-based medicinal products (CBMPs) represents a state-of-the-art approach for reducing general immunosuppression in organ transplantation. We tested multiple regulatory CBMPs in kidney transplant trials to establish the safety of regulatory CBMPs when combined with reduced immunosuppressive treatment.…”

Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. by Koshiba, T, Li, Y, Takemura, M, Wu, Y, Sakaguchi, S, Minato, N, Wood, K, Haga, H, Ueda, M, Uemoto, S

“…Immunosuppressants were completely discontinued for 54 patients as scheduled, and for 33 because of EBV infection or other complications. …”

The potential role for regulatory T-cell therapy in vascularized composite allograft transplantation. by Issa, F, Wood, K

“…However, it is limited by the need for long-term immunosuppression and high rates of acute rejection directed against skin. …”

Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells. by Francis, R, Feng, G, Tha-In, T, Lyons, I, Wood, K, Bushell, A

“…In relation to clinical tolerance induction, the data indicate that while the generation of alloreactive Treg may be critical for long-term allograft survival without chronic immunosuppression, successful protocols will also require strategies that target potential effector cells.…”

Donor reactive regulatory T cells. by Feng, G, Chan, T, Wood, K, Bushell, A

“…SUMMARY: Combined with appropriate immunosuppression, Treg generated/expanded in vivo or ex vivo may hold the final key to operational tolerance in clinical setting.…”

Measurement of T cell alloreactivity using imaging flow cytometry by Juvet, S, Moshkelgosha, S, Sanderson, S, Hester, J, Wood, K, Bushell, A

“…In the future, further development and evaluation of this method using human cells may form the basis for assays used to select patients for immunosuppression minimization, and it can be used to measure the impact of tolerogenic therapies in the clinic.…”

Immunobiology of solid organ transplantation. by Turvey, SE, Wood, K

“…The induction of tolerance would allow patients to enjoy the benefits of their transplanted organ without risking the mortality and morbidity associated with long-term pharmacological immunosuppression. In this review, we explore the immunobiology of solid organ transplantation, discussing the immunological mechanisms responsible for allograft rejection, and outlining the rational behind a range of successful experimental tolerance induction strategies.…”